文献速递前列腺癌

预测前列腺癌主动监测期间的活检结局:Canary前列腺主动监测研究风险计算器在五个大型主动监测队列中的外部验证

Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
PubMed 文献 · Eur Urol · 2019-08-24

研究利用GAP3联盟截至2017年11月的数据,在五个大型主动监测队列共5105名男性中外部验证两个Canary前列腺主动监测研究风险计算器(PASS-RCs)。两种计算器的区分度尚可(AUC分别为0.68和0.65),校准中等,在预测再分类风险10%至30%区间净获益优于多数默认策略。结论认为两种计算器通过减少不必要活检改善了检测再分类与实施监测活检之间的平衡,但实施前需根据本地情况重新校准。

要点

  • 两种PASS-RCs在五个大型主动监测队列中区分度尚可,AUC分别为0.68和0.65。
  • PASS-RCs校准中等,在预测再分类风险10%至30%区间净获益优于多数默认策略。
  • 两种PASS-RCs通过减少不必要活检改善了检测再分类与实施监测活检之间的平衡。

核心结论

  • 两种PASS-RCs通过减少不必要活检改善了检测再分类与实施监测活检之间的平衡。
  • 实施前需根据本地情况重新校准以提高临床实用性。

研究设计与样本

  • 利用Movember基金会全球行动计划(GAP3)联盟截至2017年11月的数据进行外部验证。
  • 五个验证队列(PRIAS、Johns Hopkins、Toronto、Memorial Sloan Kettering Cancer Center和University of California San Francisco)共纳入5105名主动监测男性。
  • 各队列包含429至2416名男性,中位随访时间36至84个月,主要来自西方国家的社区和学术机构。

主要发现

  • PASS-RCs区分再分类与否的能力尚可,受试者工作特征曲线下面积值分别为0.68和0.65。
  • PASS-RCs校准中等。
  • 在预测再分类风险10%至30%之间,PASS-RCs的净获益大于多数默认策略。

临床怎么用

  • 原文结论指出两种PASS-RCs通过减少不必要活检改善了检测再分类与实施监测活检之间的平衡。
  • 原文建议实施前需根据本地情况重新校准以提高临床实用性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Men with prostate cancer (PCa) on active surveillance (AS) are followed through regular prostate biopsies, a burdensome and often unnecessary intervention, not without risks. Identifying men with at a low risk of disease reclassification may help reduce the number of biopsies. OBJECTIVE: To assess the external validity of two Canary Prostate Active Surveillance Study Risk Calculators (PASS-RCs), which estimate the probability of reclassification (Gleason grade ≥7 with or without >34% of biopsy cores positive for PCa) on a surveillance biopsy, using a mix of months since last biopsy, age, body mass index, prostate-specific antigen, prostate volume, number of prior negative biopsies, and percentage (or ratio) of positive cores on last biopsy. DESIGN, SETTING, AND PARTICIPANTS: We used data up to November 2017 from the Movember Foundation's Global Action Plan (GAP3) consortium, a global collaboration between AS studies. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: External validity of the PASS-RCs for estimating reclassification on biopsy was assessed by calibration, discrimination, and decision curve analyses. RESULTS AND LIMITATIONS: Five validation cohorts (Prostate Cancer Research International: Active Surveillance, Johns Hopkins, Toronto, Memorial Sloan Kettering Cancer Center, and University of California San Francisco), comprising 5105 men on AS, were eligible for analysis. The individual cohorts comprised 429-2416 men, with a median follow-up between 36 and 84 mo, in both community and academic practices mainly from western countries. Abilities of the PASS-RCs to discriminate between men with and without reclassification on biopsy were reasonably good (area under the receiver operating characteristic curve values 0.68 and 0.65). The PASS-RCs were moderately well calibrated, and had a greater net benefit than most default strategies between a predicted 10% and 30% risk of reclassification. CONCLUSIONS: Both PASS-RCs improved the balance between detecting reclassification and performing surveillance biopsies by reducing unnecessary biopsies. Recalibration to the local setting will increase their clinical usefulness and is therefore required before implementation. PATIENT SUMMARY: Unnecessary prostate biopsies while on active surveillance (AS) should be avoided as much as possible. The ability of two calculators to selectively identify men at risk of progression was tested in a large cohort of men with low-risk prostate cancer on AS. The calculators were able to prevent unnecessary biopsies in some men. Usefulness of the calculators can be increased by adjusting them to the characteristics of the population of the clinic in which the calculators will be used.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Drost FH, Nieboer D, Morgan TM, et al. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. Eur Urol. 2019. PMID: 31451332. doi:10.1016/j.eururo.2019.07.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。